Iopamidol
- Generic Name
- Iopamidol
- Brand Names
- Isovue 200, Isovue 250, Isovue 300, Isovue 370, Isovue-M, Isovue-M 200
- Drug Type
- Small Molecule
- Chemical Formula
- C17H22I3N3O8
- CAS Number
- 60166-93-0
- Unique Ingredient Identifier
- JR13W81H44
- Background
Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
- Indication
本品用于腰、胸肌颈段脊髓造影，脑血管造影，周围动脉造影剂静脉造影；也用于心血管、冠状动脉、尿路、关节等的造影剂CT增强。
- Associated Conditions
- -
- Associated Therapies
- -
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 78
- Registration Number
- NCT06411795
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Chongqing Emergency Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT05489055
- Locations
- 🇨🇳
Chongqing Emergency Mediacl Centre, Chongqing, Chonqing, China
Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04870645
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Jennifer Lee Caswell-Jin
- Target Recruit Count
- 4
- Registration Number
- NCT04504331
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Study With Oral Isovue in Abdominopelvic CT
- Conditions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 218
- Registration Number
- NCT04453059
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Duke University
- Target Recruit Count
- 201
- Registration Number
- NCT03557385
- Locations
- 🇺🇸
Long Beach VA, Long Beach, California, United States
🇺🇸Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Durham VA, Durham, North Carolina, United States
Optimization of Contrast Agent Dose in CT With Lean Body Weight
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- IRCCS Policlinico S. Donato
- Target Recruit Count
- 274
- Registration Number
- NCT03384979
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Duke University
- Target Recruit Count
- 10
- Registration Number
- NCT03071328
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Customized Contrast Media Dose Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Duke University
- Target Recruit Count
- 166
- Registration Number
- NCT02433665
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Duke University
- Target Recruit Count
- 35
- Registration Number
- NCT02171247
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.